Evidence map›Paper›PMID 33552952›Full record

ArticleFrontiers in oncology2020

Mutational Landscape for Indian Hereditary Breast and Ovarian Cancer Cohort Suggests Need for Identifying Population Specific Genes and Biomarkers for Screening.

Mohammed Shaad N Kadri, Komal M Patel, Poonam A Bhargava, Franky D Shah, Nutan V Badgujar, Bhoomi V Tarapara, Prabhudas S Patel, Mohammed Inayatullah Shaikh, Krati Shah, Apurva Patel and 4 more

Abstract read
In one paragraph

Article in Frontiers in oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed.

  1. Review
  2. Article
  3. Frontiers in oncology · 2026
    Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Mohammed Shaad N KadriGujarat Biotechnology Research Centre, Department of Science and Technology, Government of Gujarat, Gandhinagar, India.
Komal M PatelGujarat Biotechnology Research Centre, Department of Science and Technology, Government of Gujarat, Gandhinagar, India.
Poonam A BhargavaGujarat Biotechnology Research Centre, Department of Science and Technology, Government of Gujarat, Gandhinagar, India.
Franky D ShahGujarat Cancer Research Institute, Civil Hospital, Ahmedabad, India.
Nutan V BadgujarGujarat Cancer Research Institute, Civil Hospital, Ahmedabad, India.
Bhoomi V TaraparaGujarat Cancer Research Institute, Civil Hospital, Ahmedabad, India.
Prabhudas S PatelGujarat Cancer Research Institute, Civil Hospital, Ahmedabad, India.
Mohammed Inayatullah ShaikhGujarat Biotechnology Research Centre, Department of Science and Technology, Government of Gujarat, Gandhinagar, India.
Krati ShahClinical Genetics, ONE-Centre for Rheumatology and Genetics, Vadodara, India.
Apurva PatelGujarat Cancer Research Institute, Civil Hospital, Ahmedabad, India.
Shashank PandyaGujarat Cancer Research Institute, Civil Hospital, Ahmedabad, India.
Hemangini VoraGujarat Cancer Research Institute, Civil Hospital, Ahmedabad, India.
Chaitanya G JoshiGujarat Biotechnology Research Centre, Department of Science and Technology, Government of Gujarat, Gandhinagar, India.
Madhvi N JoshiGujarat Biotechnology Research Centre, Department of Science and Technology, Government of Gujarat, Gandhinagar, India.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundBreast and ovarian cancers are the most prevalent cancers and one of the leading causes of death in Indian women. The healthcare burden of breast and ovarian cancers and the rise in mortality rate are worrying and stress the need for early detection and treatment.

methodsWe performed amplicon sequencing of 144 cases who had breast/ovarian cancer disease (total 137 cases are patients and seven are tested for BRCA1/2 carrier) Using our custom designed gene panel consisting of 14 genes, that are associated with high to moderate risk of breast and ovarian cancers. Variants were called using Torrent Variant Caller and were annotated using ThermoFisher's Ion Reporter software. Classification of variants and their clinical significance were identified by searching the variants against ClinVar database.

resultsFrom a total of 144 cases, we were able to detect 42 pathogenic mutations in [40/144] cases. Majority of pathogenic mutations (30/41) were detected in BRCA1 gene, while (7/41) pathogenic mutations were detected in BRCA2 gene, whereas, (2/41) pathogenic mutations were detected in TP53 gene and BRIP1, PALB2, and ATM genes respectively. So, BRCA genes contributed 88.09% of pathogenic mutations, whereas non-BRCA genes contributed 11.91% of pathogenic mutations. We were also able to detect 25 VUS which were predicted to be damaging by

conclusionEarly detection of cancers in the Indian population can be done by genetic screening using customized multi-gene panels. Indications of our findings show that in the Indian population, apart from the common BRCA genes, there are other genes that are also responsible for the disease. High frequency mutations detected in the study and variants of uncertain significance predicted to be damaging by

Indexed as

amplicon sequencingBRCA1 and BRCA2customized multi-gene panelgenetic testinghereditary breast and ovarian cancernext generation sequencingnon-BRCA genes

Identifiers

PMID33552952
PMCPMC7859489

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.